Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE - SFDA Drug Approval Details

Approvals/SFDA/ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE

Authorized

NCE

ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: dfdb330c6b9cba65
Company: Unknown
Type: NCE

Approval Details

Approval Id: dfdb330c6b9cba65
Drug Approval Sfda Name: ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE
Trade Name: ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE
Generic Name: TACROLIMUS
Register Number: 2803245119
Register Year: 2013
Drug Type: NCE
Route Of Administration: Oral use
Package Type: Blister
Package Size: 100
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: Store below 30°C , protect from Light
Shelf Life: 36 Months
Distribution Site: Pharmacy
Description Code: 7000001195-0.5-100000073662
Price: 347.9

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

dfdb330c6b9cba65

Type

NCE

Back to SFDA Approvals